Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

for induction treatment of moderate-to-severe ulcerative colitis (UC), with patients who failed on immunomodulators, anti-TNFα, vedolizumab or corticosteroids. The topline results indicate that ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...